KATHERINE PRICE: Open Payments
NPI 1215635180 · GREENWOOD, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,077 in 45 payments from 9 companies in 2025. Trend: 2023 $50 · 2024 $585 · 2025 $1,077
Food & beverage: $1,077
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $347 |
| ABBVIE INC. | 9 | $152 |
| Janssen Pharmaceuticals, Inc | 7 | $145 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $144 |
| Otsuka America Pharmaceutical, Inc. | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $17 |
Products named: INGREZZA, VRAYLAR, CAPLYTA, ABILIFY ASIMTUFII, SPRAVATO, TRINTELLIX, INVEGA SUSTENNA, HETLIOZ.
Industry payments across SC — which companies pay providers there.
